Literature DB >> 12654076

Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI.

Hiromi Seki1, Masaaki Shiohara, Tadao Matsumura, Natsuki Miyagawa, Mamoru Tanaka, Atsushi Komiyama, Susumu Kurata.   

Abstract

BACKGROUND: Clostridium butyricum MIYAIRI (CBM) is a probiotic bacteria used for anti-diarrheal medicine in Japan. The preventive effect of CBM was investigated for antibiotic-associated diarrhea (AAD) in children.
METHODS: One hundred and ten children who suffered from upper respiratory tract infection or gastroenteritis were divided into three groups. Twenty-seven of the patients received only antibiotics, 38 received CBM from the mid point of the antibiotic treatment and 45 concomitantly received CBM from the beginning of the antibiotic treatment. To examine the effects of CBM on AAD, the changes in intestinal flora were investigated.
RESULTS: Diarrhea was observed in 59% of the subjects who received only antibiotics, and total fecal anaerobes, especially Bifidobacterium, were remarkably decreased. In contrast, diarrhea in the subjects who received CBM from either the middle or the beginning of the antibiotic therapy was decreased to 5% and 9%, respectively. Concomitant administration of CBM increased anaerobes and prevented the decrease of Bifidobacterium in the subjects who received antibiotics.
CONCLUSIONS: Clostridium butyricum MIYAIRI is effective for both the treatment and the prophylaxis of AAD in children, as it normalizes the intestinal flora disturbed by antibiotics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654076     DOI: 10.1046/j.1442-200x.2003.01671.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  58 in total

1.  Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy.

Authors:  Izumi Shimbo; Taketo Yamaguchi; Takeo Odaka; Kenichi Nakajima; Akinori Koide; Hidehiko Koyama; Hiromitsu Saisho
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

Review 2.  A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.

Authors:  Takanori Kanai; Yohei Mikami; Atsushi Hayashi
Journal:  J Gastroenterol       Date:  2015-05-05       Impact factor: 7.527

3.  Next-generation probiotics: the spectrum from probiotics to live biotherapeutics.

Authors:  Paul W O'Toole; Julian R Marchesi; Colin Hill
Journal:  Nat Microbiol       Date:  2017-04-25       Impact factor: 17.745

Review 4.  Probiotics, prebiotics and the gastrointestinal tract in health and disease.

Authors:  Luis Vitetta; David Briskey; Hollie Alford; Sean Hall; Samantha Coulson
Journal:  Inflammopharmacology       Date:  2014-03-16       Impact factor: 4.473

5.  Effect of Clostridium butyricum supplementation on the development of intestinal flora and the immune system of neonatal mice.

Authors:  Rui-Xue Miao; Xin-Xin Zhu; Chao-Min Wan; Zhi-Ling Wang; Yang Wen; Yi-Yuan Li
Journal:  Exp Ther Med       Date:  2017-11-07       Impact factor: 2.447

Review 6.  TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.

Authors:  Sozaburo Ihara; Yoshihiro Hirata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2017-05-22       Impact factor: 7.527

7.  Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile.

Authors:  Melinda A Engevik; Kristen A Engevik; Mary Beth Yacyshyn; Jiang Wang; Daniel J Hassett; Benjamin Darien; Bruce R Yacyshyn; Roger T Worrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-31       Impact factor: 4.052

8.  Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.

Authors:  Bradley C Johnston; Alison L Supina; Sunita Vohra
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

9.  Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood.

Authors:  Xin Dai; Zixuan Guo; Danfeng Chen; Lu Li; Xueli Song; Tianyu Liu; Ge Jin; Yun Li; Yi Liu; Aihemaiti Ajiguli; Cheng Yang; Bangmao Wang; Hailong Cao
Journal:  Gut Microbes       Date:  2020-03-31

10.  Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats.

Authors:  Makoto Seo; Ikuo Inoue; Mamoru Tanaka; Noriko Matsuda; Takanari Nakano; Takuya Awata; Shigehiro Katayama; David H Alpers; Tsugikazu Komoda
Journal:  Dig Dis Sci       Date:  2013-10-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.